FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	9	,			

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden

hours per response:

0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							55(11)	J. 1110	500111		opay , to								
1. Name and Address of Reporting Person* Brooks Michael J					2. Issuer Name and Ticker or Trading Symbol Edesa Biotech, Inc. [EDSA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title) Other (specify)						
	(Last) (First) (Middle) C/O EDESA BIOTECH INC. 100 SPY COURT					3. Date of Earliest Transaction (Month/Day/Year) 11/02/2022								X Officer (give title Other (specify below) President					
(Street) MARKH (City)					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - No	on-Deriv	ative	Sec	uritie	s Ac	quired	I, Di	sposed o	of, or Be	neficia	Ily Owne	d				
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day				ction	tion 2A. Deemed Execution Date,		Transaction Disposed Of (I Code (Instr.		es Acquired (A) or Of (D) (Instr. 3, 4 and		5. Amo Securit Benefic Owned	unt of ies cially Following	Form: Direct (D) or Indirect		7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	(A) or (D)	Price	Transa	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
Common Shares 11/02/20				2022	:022		A		4,239	A	\$1.12	5(1) 3(0,480		D				
		Т	able II								posed of converti			y Owned					
1. Title of Derivative Security (Instr. 3) 2. Conversion Date (Month/Day/Year Price of Derivative Security			3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		of		6. Date Exercis Expiration Dat (Month/Day/Ye		te	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares						
Common Share Warrants (Right to Buy) ⁽²⁾	\$1.5	11/02/2022			A		2,119		(2)		(2)	Common Shares	2,119	(1)	2,119)	D		
Common Share Warrants	\$1	11/02/2022			A		2,119		(3)		(3)	Common Shares	2,119	(1)	2,119)	D		

Explanation of Responses:

(Right to Buy)⁽³⁾

- 1. The reported securities are included within 4,239 Common Shares purchased by the reporting person for \$1.1250 per Common Share. Each Common Share includes the purchase of one-half of a Class A Warrant to purchase one Common Share, and one-half of a Class B Warrant to purchase one Common Share.
- 2. Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable on the date that is the earlier to occur of 60 days from the closing date of the offering and the date a Registration Statement covering the resale of the Common Shares and Common Shares issuable upon exercise of the Warrants is declared effective (the "Initial Exercise Date") and will expire three years after the Initial Exercise Date.
- 3. Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable on the Initial Exercise Date and will expire 12 months after the Initial Exercise Date.

<u>/s/ Michael J. Brooks</u> <u>11/04/2022</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.